Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Ayumi Tatekoshi is active.

Publication


Featured researches published by Ayumi Tatekoshi.


Case Reports in Oncology | 2014

Efficacy of Enteral Supplementation Enriched with Glutamine, Fiber, and Oligosaccharide on Mucosal Injury following Hematopoietic Stem Cell Transplantation

Satoshi Iyama; Tsutomu Sato; Hiroomi Tatsumi; Akari Hashimoto; Ayumi Tatekoshi; Yusuke Kamihara; Hiroto Horiguchi; Soushi Ibata; Kaoru Ono; Kazuyuki Murase; Kohichi Takada; Yasushi Sato; Tsuyoshi Hayashi; Koji Miyanishi; Emi Akizuki; Takayuki Nobuoka; Toru Mizugichi; Rishu Takimoto; Masayoshi Kobune; Koichi Hirata; Junji Kato

The combination of glutamine, fiber and oligosaccharides (GFO) is thought to be beneficial for alleviating gastrointestinal mucosal damage caused by chemotherapy. A commercial enteral supplementation product (GFO) enriched with these 3 components is available in Japan. We performed a retrospective study to test whether oral GFO decreased the severity of mucosal injury following hematopoietic stem cell transplantation (HSCT). Of 44 HSCT patients, 22 received GFO and 22 did not. Severity of diarrhea/mucositis, overall survival, weight loss, febrile illness/documented infection, intravenous hyperalimentation days/hospital days, engraftment, acute and chronic GVHD, and cumulative incidence of relapse were studied. Sex, age, performance status, diagnosis, disease status, and treatment variables were similar in both groups. There were fewer days of diarrhea grade 3-4 in patients receiving GFO than in those who did not (0.86 vs. 3.27 days); the same was true for days of mucositis grade 3-4 (3.86 vs. 6.00 days). Survival at day 100 was 100% in the GFO group, but only 77.3% for the patients not receiving GFO (p = 0.0091, log-rank test). Weight loss and the number of days of intravenous hyperalimentation were better in the GFO group (p < 0.001 and p = 0.0014, respectively). Although not significant, less gut bacterial translocation with Enterococcus species developed in the GFO group (p = 0.0728) than in the non-GFO group. Other outcomes were not affected. To the best of our knowledge, this is the first comparative clinical study of GFO supplementation to alleviate mucosal injury after allo-HSCT. We conclude that glutamine, fiber and oligosaccharide supplementation is an effective supportive therapy to decrease the severity of mucosal damage in HSCT.


Haematologica | 2016

Extracellular vesicle miR-7977 is involved in hematopoietic dysfunction of mesenchymal stromal cells via poly(rC) binding protein 1 reduction in myeloid neoplasms

Hiroto Horiguchi; Masayoshi Kobune; Shohei Kikuchi; Yoshida M; Masaki Murata; Kazuyuki Murase; Satoshi Iyama; Kohichi Takada; Tsutomu Sato; Kaoru Ono; Akari Hashimoto; Ayumi Tatekoshi; Yusuke Kamihara; Yutaka Kawano; Koji Miyanishi; Norimasa Sawada; Junji Kato

The failure of normal hematopoiesis is observed in myeloid neoplasms. However, the precise mechanisms governing the replacement of normal hematopoietic stem cells in their niche by myeloid neoplasm stem cells have not yet been clarified. Primary acute myeloid leukemia and myelodysplastic syndrome cells induced aberrant expression of multiple hematopoietic factors including Jagged-1, stem cell factor and angiopoietin-1 in mesenchymal stem cells even in non-contact conditions, and this abnormality was reverted by extracellular vesicle inhibition. Importantly, the transfer of myeloid neoplasm-derived extracellular vesicles reduced the hematopoietic supportive capacity of mesenchymal stem cells. Analysis of extracellular vesicle microRNA indicated that several species, including miR-7977 from acute myeloid leukemia cells, were higher than those from normal CD34+ cells. Remarkably, the copy number of miR-7977 in bone marrow interstitial fluid was elevated not only in acute myeloid leukemia, but also in myelodysplastic syndrome, as compared with lymphoma without bone marrow localization. The transfection of the miR-7977 mimic reduced the expression of the posttranscriptional regulator, poly(rC) binding protein 1, in mesenchymal stem cells. Moreover, the miR-7977 mimic induced aberrant reduction of hematopoietic growth factors in mesenchymal stem cells, resulting in decreased hematopoietic-supporting capacity of bone marrow CD34+ cells. Furthermore, the reduction of hematopoietic growth factors including Jagged-1, stem cell factor and angiopoietin-1 were reverted by target protection of poly(rC) binding protein 1, suggesting that poly(rC) binding protein 1 could be involved in the stabilization of several growth factors. Thus, miR-7977 in extracellular vesicles may be a critical factor that induces failure of normal hematopoiesis via poly(rC) binding protein 1 suppression.


PLOS ONE | 2016

Narrow-Band Ultraviolet B Phototherapy Ameliorates Acute Graft-Versus-Host Disease of the Intestine by Expansion of Regulatory T Cells.

Akari Hashimoto; Tsutomu Sato; Satoshi Iyama; Yoshida M; Soushi Ibata; Ayumi Tatekoshi; Yusuke Kamihara; Hiroto Horiguchi; Kazuyuki Murase; Yutaka Kawano; Kohichi Takada; Koji Miyanishi; Masayoshi Kobune; Shingo Ichimiya; Junji Kato

Narrowband ultraviolet B (NB-UVB) has been widely used in dermatological phototherapy. As for the application of NB-UVB phototherapy to graft-versus-host disease (GVHD), we previously reported that it was highly efficacious for cutaneous lesions of acute GVHD (aGVHD) and that expansion of regulatory T (Treg) cells induced by NB-UVB might be one of the mechanisms. In order to examine whether NB-UVB irradiation through expansion of Treg cells is effective for the treatment of not only cutaneous aGVHD but also aGVHD of inner organs such as the intestine or liver, we conducted experiments in which a murine lethal aGVHD model, characterized by severe involvement of the intestine, was irradiated with NB-UVB. We found that NB-UVB irradiation improved the clinical score and survival rate. The pathological score of aGVHD was improved in all affected organs: intestine, liver, and skin. In the serum of mice irradiated with NB-UVB, the levels of Treg cells-associated cytokines such as transforming growth factor beta (TGFβ) and interleukin-10 (IL-10) were elevated. The numbers of infiltrating Treg cells in inflamed tissue of the intestine and those in spleen were increased in mice treated with NB-UVB. This is the first report demonstrating that NB-UVB phototherapy has the ability to ameliorate intestinal aGVHD through the expansion of Treg cells.


Blood Cancer Journal | 2014

A novel strategy inducing autophagic cell death in Burkitt's lymphoma cells with anti-CD19-targeted liposomal rapamycin

Kaoru Ono; Tsutomu Sato; Satoshi Iyama; Ayumi Tatekoshi; Akari Hashimoto; Yusuke Kamihara; Hiroto Horiguchi; Shohei Kikuchi; Yutaka Kawano; Kohichi Takada; Tsuyoshi Hayashi; Koji Miyanishi; Yasushi Sato; Rishu Takimoto; Masayoshi Kobune; Junji Kato

Relapsed or refractory Burkitts lymphoma often has a poor prognosis in spite of intensive chemotherapy that induces apoptotic and/or necrotic death of lymphoma cells. Rapamycin (Rap) brings about autophagy, and could be another treatment. Further, anti-CD19-targeted liposomal delivery may enable Rap to kill lymphoma cells specifically. Rap was encapsulated by anionic liposome and conjugated with anti-CD19 antibody (CD19-GL-Rap) or anti-CD2 antibody (CD2-GL-Rap) as a control. A fluorescent probe Cy5.5 was also liposomized in the same way (CD19 or CD2-GL-Cy5.5) to examine the efficacy of anti-CD19-targeted liposomal delivery into CD19-positive Burkitts lymphoma cell line, SKW6.4. CD19-GL-Cy5.5 was more effectively uptaken into SKW6.4 cells than CD2-GL-Cy5.5 in vitro. When the cells were inoculated subcutaneously into nonobese diabetic/severe combined immunodeficiency mice, intravenously administered CD19-GL-Cy5.5 made the subcutaneous tumor fluorescent, while CD2-GL-Cy5.5 did not. Further, CD19-GL-Rap had a greater cytocidal effect on not only SKW6.4 cells but also Burkitts lymphoma cells derived from patients than CD2-GL-Rap in vitro. The specific toxicity of CD19-GL-Rap was cancelled by neutralizing anti-CD19 antibody. The survival period of mice treated with intravenous CD19-GL-Rap was significantly longer than that of mice treated with CD2-GL-Rap after intraperitoneal inoculation of SKW6.4 cells. Anti-CD19-targeted liposomal Rap could be a promising lymphoma cell-specific treatment inducing autophagic cell death.


Journal of Medical Case Reports | 2016

Isoform D of vascular endothelial growth factor in systemic capillary leak syndrome: a case report.

Soushi Ibata; Tsutomu Sato; Kohichi Takada; Ayumi Tatekoshi; Akari Hashimoto; Yusuke Kamihara; Wataru Jomen; Hiroto Horiguchi; Kaoru Ono; Kazuyuki Murase; Satoshi Iyama; Koji Miyanishi; Yasushi Sato; Rishu Takimoto; Masayoshi Kobune; Junji Kato

BackgroundSystemic capillary leak syndrome is a rare condition characterized by episodic attacks of hypovolemia due to systemic capillary hyperpermeability, which results in profound hypotension and edema. Although the implication of vascular endothelial growth factor, angiopoietin-2, and C-X-C motif chemokine 10 has been suggested, the pathogenesis of systemic capillary leak syndrome remains unclear. In this report, we describe a case of systemic capillary leak syndrome in which serum isoform D of vascular endothelial growth factor was elevated. To the best of our knowledge, this is the first reported case of systemic capillary leak syndrome in which isoform D of vascular endothelial growth factor is suggested as the plausible biomarker.Case presentationA 41-year-old Japanese man was transferred to our emergency department. He was hypotensive, tachycardic, and edematous over the trunk and all four limbs. He received aggressive intravenous fluid therapy and underwent fasciotomy of the right forearm to prevent muscle necrosis. A diagnosis of systemic capillary leak syndrome was suspected. The presence of serum monoclonal immunoglobulin G and κ light chain supported this diagnosis. Prevention of hypotensive crises was unsuccessfully attempted with theophylline, intravenous immunoglobulin, high-dose dexamethasone, bortezomib, melphalan, and prednisolone; however, the patient’s attacks dramatically disappeared after the introduction of thalidomide. The serum of the patient was stored soon after the onset of hypotensive crisis and analyzed to profile possible mediators responsible for the capillary leak. The concentration of vascular endothelial growth factor, angiopoietin-2, and C-X-C motif chemokine 10 were all within normal ranges. Meanwhile, we found that isoform D of vascular endothelial growth factor was elevated, which was normalized after the introduction of thalidomide.ConclusionsIn our patient, isoform D of vascular endothelial growth factor (instead of vascular endothelial growth factor) may have been a causative factor of hypotensive crises, since isoform D contributes to vascular endothelial growth factor receptor-2 signaling, which is the major mediator of the permeability-enhancing effects of vascular endothelial growth factor. We suggest the measurement of isoform D of vascular endothelial growth factor in patients with systemic capillary leak syndrome in whose serum vascular endothelial growth factor is not elevated.


The Japanese journal of clinical hematology | 2016

[Neurolymphomatosis of the sciatic nerve diagnosed by FDG-PET/CT].

Makoto Usami; Kazuyuki Murase; Takada K; Iijima K; Yoshida M; Ayumi Tatekoshi; Akari Hashimoto; Satoshi Iyama; Tsutomu Sato; Masayoshi Kobune; Takimoto R; Kaya M; Yamashita T; Morita R; Hasegawa T; Junji Kato

Neurolymphomatosis is a rare manifestation of malignant lymphoma. The involvement of peripheral nerves has mostly been described as dissemination of a systemic lymphoma. In contrast, primary peripheral nerve lymphoma is extremely rare. A 68-year-old man presented in January 2014 with a sensory disturbance in the left lower extremity. There were no obvious findings on MRI or CT that could account for his symptoms. After 1 year of symptomatic treatment, the patient was managed conservatively for an additional year. However, his symptoms worsened. FDG-PET/CT showed high FDG uptake in the left sciatic nerve. Biopsy of the lesion revealed diffuse large B cell lymphoma.


Case Reports in Oncology | 2014

Combination Chemotherapy of Azacitidine and Cetuximab for Therapy-Related Acute Myeloid Leukemia following Oxaliplatin for Metastatic Colorectal Cancer

Akari Hashimoto; Kohichi Takada; Hiroto Horiguchi; Tsutomu Sato; Satoshi Iyama; Kazuyuki Murase; Yusuke Kamihara; Kaoru Ono; Ayumi Tatekoshi; Tsuyoshi Hayashi; Koji Miyanishi; Yasushi Sato; Tomohisa Furuhata; Masayoshi Kobune; Rishu Takimoto; Koichi Hirata; Junji Kato

Therapy-related leukemia (TRL) has been reported to occur after treatment with alkylating agents and/or topoisomerase II inhibitors. Oxaliplatin (OXP) is used as a key drug for the treatment of colorectal cancer (CRC). Cisplatin and carboplatin have been linked with TRL, but the involvement of OXP is questionable. A 74-year-old male was diagnosed with peritoneal metastasis from CRC in July 2011. The patient received nine cycles of 5-fluorouracil (5-FU), leucovorin (LV), and OXP (mFOLFOX-6 regimen) and three cycles of 5-FU and LV only, resulting in a clinical complete response. However, recurrence of CRC was detected by CT within 3 months after the last course of chemotherapy. In April 2013, laboratory tests showed pancytopenia and 15% blast cells. A bone marrow examination revealed multilineage dysplasia and 20.4% myeloblasts. Cytogenetic analysis indicated a complex karyotype that included chromosome 5 and 7 abnormalities. The patient was diagnosed with TRL and treated with a combination of azacitidine (AZA) and cetuximab (Cmab) for both cancers. AZA might be useful in TRL when a patient needs to be treated simultaneously for more than one primary cancer because of its low toxicity. Moreover, Cmab is an effective therapeutic tool in TRL patients with metastatic CRC with the wild-type K-ras gene.


International Journal of Hematology | 2014

Narrowband ultraviolet B phototherapy ameliorates acute graft-versus-host disease by a mechanism involving in vivo expansion of CD4+CD25+Foxp3+ regulatory T cells

Satoshi Iyama; Kazuyuki Murase; Tsutomu Sato; Akari Hashimoto; Ayumi Tatekoshi; Hiroto Horiguchi; Yusuke Kamihara; Kaoru Ono; Shohei Kikuchi; Kohichi Takada; Yutaka Kawano; Tsuyoshi Hayashi; Koji Miyanishi; Yasushi Sato; Rishu Takimoto; Masayoshi Kobune; Satoru Mori; Junji Kato; Toshiharu Yamashita


International Journal of Hematology | 2014

A role for peripherally inserted central venous catheters in the prevention of catheter-related blood stream infections in patients with hematological malignancies

Toshiro Sakai; Kyuhei Kohda; Yuichi Konuma; Yasuko Hiraoka; Yukari Ichikawa; Kaoru Ono; Hiroto Horiguchi; Ayumi Tatekoshi; Takada K; Satoshi Iyama; Junji Kato


Gan to kagaku ryoho. Cancer & chemotherapy | 2014

Effective treatment of metastatic rhabdomyosarcoma with pazopanib

Akari Hashimoto; Takada K; Takimoto R; Hiroto Horiguchi; Tsutomu Sato; Satoshi Iyama; Kazuyuki Murase; Kaoru Ono; Ayumi Tatekoshi; Tsuyoshi Hayashi; Koji Miyanishi; Yasushi Sato; Masayoshi Kobune; Yasuo Hirayama; Kitamura H; Nakanishi K; Naoya Masumori; Tadashi Hasegawa; Junji Kato

Collaboration


Dive into the Ayumi Tatekoshi's collaboration.

Top Co-Authors

Avatar

Junji Kato

Sapporo Medical University

View shared research outputs
Top Co-Authors

Avatar

Satoshi Iyama

Sapporo Medical University

View shared research outputs
Top Co-Authors

Avatar

Tsutomu Sato

Sapporo Medical University

View shared research outputs
Top Co-Authors

Avatar

Akari Hashimoto

Sapporo Medical University

View shared research outputs
Top Co-Authors

Avatar

Masayoshi Kobune

Sapporo Medical University

View shared research outputs
Top Co-Authors

Avatar

Hiroto Horiguchi

Sapporo Medical University

View shared research outputs
Top Co-Authors

Avatar

Kaoru Ono

Sapporo Medical University

View shared research outputs
Top Co-Authors

Avatar

Kazuyuki Murase

Sapporo Medical University

View shared research outputs
Top Co-Authors

Avatar

Koji Miyanishi

Sapporo Medical University

View shared research outputs
Top Co-Authors

Avatar

Yusuke Kamihara

Sapporo Medical University

View shared research outputs
Researchain Logo
Decentralizing Knowledge